Source: Benzinga

Zosano Pharma: ZOSANO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zosano Pharma Corp. on Behalf of Zosano Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zosano Pharma Corp. (NASDAQ:ZSAN) on behalf of Zosano stockholders. Our investigation concerns whether Zosano has violated the federal securities laws and/or engaged in other unlawful business practices.Click here to participate in the action.On September 30, 2020, Zosano Pharma Corp. stunned the market when it announced that it had received "a discipline review letter (DRL) from the U.S. Food and Drug Administration" in connection with Zosano's new drug application for Qtrypta . Per Zosano's announcement, the FDA "raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic ...Full story available on

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more